Pharmaceutical combination of a corticosteroid and an antihistamine for the treatment and control of the inflammatory component of allergic processes

MX439229BActive Publication Date: 2026-10-05LAB SILANES S A DE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MX2022015335
Authority / Receiving Office
MX · MX
Patent Type
Patents
Current Assignee / Owner
Filing Date
2022-12-02
Publication Date
2026-10-05
Estimated Expiration
2040-12-04

AI Technical Summary

Technical Problem

Existing pharmaceutical compositions of desloratadine and betamethasone face challenges in maintaining stability and immediate release due to their physicochemical properties, particularly desloratadine's degradation under humidity and temperature, and the need for a stable, single-dose formulation for treating allergic and inflammatory processes.

Method used

A solid, stable, immediate-release pharmaceutical composition comprising desloratadine and betamethasone, optimized with specific excipients like microcrystalline cellulose, pregelatinized starch, and moisture barrier coatings, ensuring stability and controlled release.

Benefits of technology

The composition provides a synergistic effect for the treatment of allergic and inflammatory conditions, maintaining dissolution and bioavailability, and is suitable for conditions such as atopic dermatitis, urticaria, and allergic rhinitis, with demonstrated stability and effective drug release.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention combines the drugs desloratadine and betamethasone in a single dosage unit, which represents a set of important technological challenges due to the physicochemical properties and the difference in doses to guarantee obtaining a stable product for the treatment of allergic and inflammatory processes in a subject.
Need to check novelty before this filing date? Find Prior Art